Navigation Links
Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
Date:2/26/2008

EMERYVILLE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has appointed N. Anthony Coles, M.D., president, chief executive officer and a member of the company's board of directors, effective March 31, 2008. Dr. Coles succeeds Hollings C. Renton, who announced his retirement plans last October. Mr. Renton is retiring as president, chief executive officer, chairman and member of the Onyx Board of Directors on the same date.

"Tony is the ideal person to lead Onyx as we build on the success of Nexavar," said Mr. Renton, president, chief executive officer, and chairman of Onyx. "He is a proven leader with a track record of success in building commercial teams and working with corporate collaborators to maximize product opportunities. His extensive executive and operations-based background will be a major contributor to driving value for Onyx, and we are delighted that he will be joining the company."

"It is an honor and a privilege to be joining Onyx at this exciting time in the company's history," said Dr. Coles. "I believe the Nexavar franchise holds tremendous commercial growth potential and further clinical promise. Together with Onyx's talented employees and strong partner, Bayer, we intend to bring the unique benefits of Nexavar to cancer patients around the globe. Through this and other initiatives, we look forward to achieving our goals and building sustainable long-term value for stockholders."

"The members of the Onyx board welcome Tony and thank Hollings for his dedicated leadership over the last 15 years," said Wendell Wierenga, Ph.D., a member of the Onyx board and chairman of the nominating and governance committee. "During Hollings' tenure, Nexavar was discovered, developed, approved in two indications, and successfully launched. On behalf of the company, we appreciate his vision and success commercializing this promising new cancer therapeutic."

Most recently Dr. Coles was president, chief executive officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel therapeutics. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, Dr. Coles held a number of executive positions while at Bristol-Myers Squibb Company, including senior vice president of strategy and policy; senior vice president of marketing and medical affairs, neuroscience/infectious diseases/dermatology; vice president, Western area sales cardiovascular and metabolic business unit for U.S. primary care; and vice president, cardiovascular global marketing. From 1992 until 1996, Dr. Coles was at Merck & Co., Inc., most recently as vice president of the hypertension and heart failure business group.

Dr. Coles earned his M.D. degree from Duke University. Subsequent to completing his internship and residency at Massachusetts General Hospital, Dr. Coles was a cardiovascular research fellow at Harvard Medical School. He also holds a master's degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a trustee for Johns Hopkins University and Boston Medical Center, and as a director of FoldRx Pharmaceuticals, Inc.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding Dr. Coles' anticipated contributions to Onyx, the progress and results of the clinical development, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NPS Pharmaceuticals Announces Senior Management Changes
2. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
3. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
6. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
7. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
8. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
9. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):